Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | IDE | P14735 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.52 |
| ▸ | HLCS | P50747 | 6/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13572339 | 0.88 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28434108 | 0.85 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL4310068 | 0.84 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10140322 | 0.84 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20641181 | 0.84 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12186905 | 0.84 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29085909 | 0.83 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28163095 | 0.80 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22290232 | 0.80 | TDP1 (0.82) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8392745 | 0.79 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329178-B2 | Antibodies against CXCR4 and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-1871807-B1 | ANTIBODIES AGAINST CXCR4 AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20110250165-A1 | Antibodies against CXCR4 and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | disclosed |
| US-7741024-B2 | Immunogenic proteoliposomes, and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1871807-A2 | ANTIBODIES AGAINST CXCR4 AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070292436-A1 | IMMUNOGENIC PROTEOLIPOSOMES, AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-7276579-B2 | Immunogenic proteoliposomes, and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1246607-B1 | PROTEOLIPOSOMES CONTAINING AN INTEGRAL MEMBRANE PROTEIN HAVING ONE OR MORE TRANSMEMBRANE DOMAINS | DANA FARBER CANCER INST INC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006089141-A2 | ANTIBODIES AGAINST CXCR4 AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1345623-A4 | IMMUNOGENIC PROTEOLIPOSOMES, AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6761902-B2 | SURROUNDS AN ELLOPTIOD RO SPEHRICAL SHAPE WHICH CONTAINS AN ATTRACTANT SUCH AS STREPTAVIDIN OR AVIDIN AND IS ANCHORED TO TO THE PROTEIN; ISOLATION AND PURIFICATION WHILE MAINTAINING IN A WILD-TYPE CONFORMATION | DANA-FARBER CANCER INSTITUTE, INC. | 2004-07-13 | — | — | US | disclosed |
| US-20040109887-A1 | Immunogenic proteoliposomes, and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-06-10 | — | — | US | disclosed |
| EP-1345623-A2 | IMMUNOGENIC PROTEOLIPOSOMES, AND USES THEREOF | Dana-Farber Cancer Institute Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002056831-A9 | IMMUNOGENIC PROTEOLIPOSOMES, AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002056831-A2 | IMMUNOGENIC PROTEOLIPOSOMES, AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20010034432-A1 | Proteoliposomes containing an integral membrane protein having one or more transmembrane domains | DANA-FARBER CANCER INSTITUTE, INC. | 2001-10-25 | — | — | US | disclosed |